FOXO4-DRI

The Senolytic Peptide Targeting Cellular Aging at Its Root

FOXO4-DRI is a synthetic peptide designed to selectively eliminate senescent cells. Senescent cells are damaged or aged cells that have stopped dividing but refuse to die. They accumulate in tissues over time, release inflammatory compounds, and contribute to the deterioration associated with aging. Unlike supplements that attempt to support longevity indirectly, FOXO4- DRI targets a defined molecular mechanism of aging that has been validated in preclinical research. The peptide was developed by Dr. Peter de Keizer and colleagues at Erasmus University Medical Center in the Netherlands. Their groundbreaking 2017 study, published in Cell, demonstrated that FOXO4-DRI could selectively kill senescent cells in mice without harming healthy cells, leading to measurable improvements in fitness, fur density, and kidney function. The name comes from its mechanism: it is a D-Retro-Inverso (DRI) modified version of a portion of the FOXO4 protein. The DRI modification means the normal L-amino acids have been replaced with D-amino acids in a reversed sequence. This makes the peptide resistant to normal enzymatic breakdown, allowing it to remain active in the body much longer than a standard peptide. FOXO4-DRI belongs to a class of compounds called senolytics, which specifically target and eliminate senescent cells. Other senolytics include the drug combination of dasatinib plus quercetin and BCL-2 inhibitors like ABT-263. What makes FOXO4-DRI unique is its selectivity: in the original research, it showed an 11.73-fold preference for killing senescent cells versus healthy cells. FOXO4-DRI is also known by the synonym Proxofim. It is a 46-amino acid peptide with a molecular formula of C228H388N86O64 and a molecular weight of approximately 5,358 Da.

What Are Senescent Cells and Why They Matter

Cellular senescence is a protective process that prevents damaged cells from dividing. However, when senescent cells accumulate, they become harmful. These cells:

• Refuse to undergo apoptosis (programmed cell death)
• Secrete inflammatory cytokines known as the senescence-associated secretory phenotype

(SASP)

• Impair tissue repair and regeneration
• Disrupt neighboring healthy cells

Excess senescent cell burden has been linked to cardiovascular disease, metabolic dysfunction, neurodegeneration, osteoarthritis, fibrosis, and accelerated biological aging.

How FOXO4-DRI Works (Mechanism of Action) To understand FOXO4-DRI, it is necessary to understand what keeps senescent cells alive when they should die.

The Role of p53 in Healthy Cells In healthy cells, the protein p53 acts as a guardian. When a cell becomes damaged beyond repair, p53 triggers apoptosis so the cell can be cleared and replaced. This is how the body maintains healthy tissue.

How Senescent Cells Hijack This System

In senescent cells, this system is hijacked. The FOXO4 protein binds to p53 and sequesters it in the nucleus, preventing p53 from initiating apoptosis. The damaged cell stays alive, accumulating and secreting inflammatory molecules called the senescence-associated secretory phenotype (SASP). These inflammatory signals damage surrounding healthy tissue and promote further dysfunction.

How FOXO4-DRI Disrupts This Interaction

FOXO4-DRI works by disrupting this protective interaction:

• The peptide enters cells and competes with endogenous FOXO4 for binding to p53
• When FOXO4-DRI binds p53 instead of FOXO4, p53 is released from nuclear

sequestration

• Free p53 translocates to the mitochondria where it triggers apoptosis
• The senescent cell dies and is cleared by normal immune processes

The key insight is that healthy cells do not have the same FOXO4-p53 nuclear interaction keeping them alive. They use other survival mechanisms. When FOXO4-DRI disrupts this specific interaction, only senescent cells that depend on it are affected. Healthy cells continue functioning normally.

The DRI Modification

The DRI modification is critical to the peptide’s function. Standard L-peptides would be rapidly degraded by cellular enzymes. The D-amino acid structure makes FOXO4-DRI resistant to proteolysis, allowing it to accumulate in cells at therapeutic concentrations and remain stable for 72 hours or more after administration.

Benefits

Selective Senescent Cell Clearance

The primary benefit is targeted elimination of dysfunctional senescent cells without collateral damage to healthy tissue. In the original mouse studies, FOXO4-DRI treatment resulted in measurable reductions in senescent cell markers across multiple organ systems.

Improved Physical Function

Aged mice treated with FOXO4-DRI showed increased exploratory behavior, greater responsiveness to physical stimuli, and increased voluntary running wheel activity. The accelerated aging model mice (XpdTTD/TTD) increased their running distance from 1.37 km/day to levels approaching normal mice after treatment.

Tissue Regeneration and Repair

By clearing senescent cells, FOXO4-DRI creates space for healthy cells to regenerate. Studies have shown improvements in kidney function markers, fur density, and tissue architecture in aged mice after treatment.

Reduced Inflammation

Senescent cells secrete pro-inflammatory factors (SASP) that contribute to chronic low-grade inflammation associated with aging. Clearing these cells reduces the systemic inflammatory burden.

Testosterone Restoration

A 2020 study showed that FOXO4-DRI treatment in aged mice increased serum testosterone levels and improved testicular function by selectively clearing senescent Leydig cells. This has implications for male late-onset hypogonadism.

Chemotherapy Recovery

The original research showed FOXO4-DRI could neutralize the toxic effects of doxorubicin (a chemotherapy drug) by clearing the senescent cells it creates. This suggests potential applications in cancer recovery.

Cartilage Regeneration

A 2021 study demonstrated that FOXO4-DRI selectively removed senescent chondrocytes from in vitro expanded human cartilage cells without harming non-senescent chondrocytes. This suggests potential applications for cartilage regeneration and joint health.

Radiation-Induced Fibrosis

Research has shown that FOXO4-DRI can alleviate radiation-induced pulmonary fibrosis by targeting senescence-like fibroblasts, while simultaneously radiosensitizing non-small cell lung cancer cells by clearing senescent cancer-associated fibroblasts.

What the Science Shows

FOXO4-DRI has strong preclinical data but no completed human clinical trials. The evidence comes primarily from mouse studies and in vitro cellular models.

Baar et al. (2017), Cell — The Landmark Study

This landmark paper established the mechanism and demonstrated efficacy in multiple mouse models:

• FOXO4-DRI showed 11.73-fold selectivity for senescent versus healthy cells
• In fast-aging XpdTTD/TTD mice, treatment restored fitness markers including fur

density and exploratory behavior

• Running wheel activity increased significantly
• Kidney function (serum creatinine, plasma urea) improved
• Liver function markers improved
• Treatment was administered intraperitoneally at 5 mg/kg every other day for three doses
• Treatment was well tolerated under the conditions tested

Zhang et al. (2020), Aging — Testosterone Restoration

This study examined FOXO4-DRI effects on age-related testosterone decline:

• Naturally aged mice (20 to 24 months) received 5 mg/kg intraperitoneally every other

day for three doses

• 30 days after treatment, serum testosterone levels increased significantly
• Senescent cell markers (p53, p21, p16) decreased in testicular tissue
• Testosterone synthesis enzymes (3β-HSD, CYP11A1) increased
• No significant changes in body weight or testis weight, indicating targeted effects

Xu (Huang) et al. (2021), Frontiers in Bioengineering and Biotechnology —

Chondrocyte Study

This study examined FOXO4-DRI effects on expanded human chondrocytes:

• Senescent chondrocytes (PDL9) showed significant reduction after treatment
• Senescence markers (SA-β-gal, p53, p16, p21) all decreased
• Non-senescent chondrocytes (PDL3) showed no noticeable cell loss
• Results suggest potential applications for cartilage regeneration and joint health

Bourgeois et al. (2025), Nature Communications — Structural Insights This recent study provided detailed structural characterization of how FOXO4-DRI interacts with p53:

• Identified the disordered p53 transactivation domain as the specific target of FOXO4 and
• Provided molecular-level understanding of the FOXO4-p53 interaction that FOXO4-DRI

disrupts

• Advanced understanding of the senolytic mechanism at the structural biology level

Dosing Protocol

FOXO4-DRI dosing in humans is not established through clinical trials. The protocols below are extrapolated from mouse studies and community experience.

Understanding the Dose Context

The original mouse studies used 5 mg/kg administered intraperitoneally every other day for three total doses. For a 60 kg human, direct translation would suggest approximately 300 mg per dose. However, peptide doses do not scale linearly between species, and intraperitoneal injection is not practical for human self-administration. Community protocols use much lower doses based on subcutaneous administration and the observation that peptide pharmacokinetics differ significantly by route.

Why Dosing Is Conservative

FOXO4-DRI targets p53, a critical tumor suppressor protein. While the mechanism is designed to be senescent-cell specific, overly aggressive dosing raises theoretical concerns about off-target effects. The conservative approach used by most self-experimenters reflects appropriate caution with an uncharacterized compound.

Standard Protocol

Protocol Dose Route Frequency Duration Conservative 2 to 3 mg Subcutaneous Every other day 6 days (3 doses) Standard 3 to 5 mg Subcutaneous Every other day 6 days (3 doses) Aggressive 5 to 10 mg Subcutaneous Every other day 6 days (3 doses)

Most protocols repeat this short cycle one to three times per year, allowing significant time between treatments for the body to clear senescent cells and regenerate tissue.

Alternative Protocols

Some practitioners use daily low-dose protocols:

• 0.3 to 0.5 mg daily for 7 days
• Repeat every other week

The rationale is that consistent low-level disruption of FOXO4-p53 interactions may be more effective than intermittent high doses. However, this approach has less precedent.

Why the Short Cycles

Senescent cell clearance is not an ongoing process requiring continuous treatment. The goal is to eliminate accumulated senescent cells, then allow healthy tissue to regenerate. Repeating treatment one to three times per year addresses new senescent cells that accumulate over time without maintaining constant peptide exposure.

Cycling Rationale

Long rest periods between treatments serve multiple purposes:

• Allow cleared senescent cells to be replaced by healthy tissue
• Reduce theoretical risk of off-target effects from chronic p53 modulation
• Enable assessment of treatment response before repeating

Draw Volumes by Vial Size

10 mg Vial (2 mL reconstitution = 5 mg/mL)

Dose Volume Units on Syringe 2 mg 0.40 mL 40 units 3 mg 0.60 mL 60 units 5 mg 1.00 mL 100 units 10 mg 2.00 mL Full vial

10 mg Vial (1 mL reconstitution = 10 mg/mL)

Dose Volume Units on Syringe 2 mg 0.20 mL 20 units 3 mg 0.30 mL 30 units 5 mg 0.50 mL 50 units 10 mg 1.00 mL 100 units

At 3 mg every other day for three doses (9 mg total per cycle), a single 10 mg vial provides one complete treatment cycle.

Reconstitution Instructions

1. Remove the plastic cap from the vial and wipe the rubber stopper with an alcohol swab. 2. Draw 1 to 2 mL of bacteriostatic water into a sterile syringe. 3. Insert the needle through the rubber stopper at an angle. 4. Direct the stream of water down the inside wall of the vial, not directly onto the powder. 5. Allow the water to gently dissolve the peptide without shaking or swirling aggressively. 6. If any powder remains undissolved after 2 to 3 minutes, gently roll the vial between your palms. 7. The solution should be clear and colorless when fully reconstituted. 8. Label the vial with the date and concentration.

FOXO4-DRI is a longer peptide (46 amino acids) than most research peptides, which may affect dissolution time. Be patient and avoid aggressive agitation.

Side Effects

Reported Side Effects

Due to the lack of human clinical trials, side effect data comes primarily from anecdotal reports:

• Injection site reactions (redness, mild irritation)
• Transient fatigue in some users
• Mild flu-like symptoms reported by some during the clearance phase
• Temporary muscle soreness

Theoretical Concerns

Because FOXO4-DRI affects p53 function, there are theoretical concerns that warrant caution:

• p53 is a critical tumor suppressor. Chronic or excessive modulation could theoretically

affect cancer surveillance, though the peptide’s senescent-cell specificity should minimize this risk.

• Unknown long-term effects from repeated senescent cell clearance.
• Potential for excessive apoptosis if dosing is too aggressive.
• Over-aggressive senolysis could theoretically impair wound healing or stem cell niches if

misused.

What Self-Experimenters Report

Anecdotal reports from self-experimenters describe a range of experiences:

• Some report significant improvements in chronic pain, joint function, and energy.
• Others report minimal noticeable effects.
• Side effects appear generally mild when protocols are followed conservatively.
• Some users describe temporary worsening before improvement as senescent cells are

cleared.

Safety Observations from Animal Studies

Across published studies, FOXO4-DRI appears well tolerated in animal models. The original Cell paper noted the treatment was well tolerated under conditions tested. No serious adverse effects have been documented in the published literature. However, human safety data does not exist.

Contraindications and Precautions

Should Avoid

• Individuals with active cancer or a history of cancer (p53 modulation warrants extreme

caution)

• Pregnant or breastfeeding women (insufficient safety data)
• Children or young adults (senescent cell burden is typically not significant before middle

age)

• Anyone with compromised immune function (clearance of dying cells requires functional

immunity)

• Those taking immunosuppressive medications

Use with Care

• Individuals over 65 (may have higher senescent cell burden; start conservative)
• Those with autoimmune conditions (unclear how senescent cell clearance affects immune

regulation)

• Anyone taking medications that affect p53 or apoptosis pathways
• People with liver or kidney impairment (unknown clearance dynamics)

Comparison to Other Senolytics

Compound Mechanism Selectivity Route Human Data Access FOXO4-DRI FOXO4-p53 High SubQ None Research disruption Dasatinib + Tyrosine kinase + Moderate Oral Phase 2 trials Rx/OTC Quercetin multiple Fisetin Multiple pathways Low- Oral Early trials OTC

Moderate

ABT-263 BCL-2 inhibition Moderate Oral Cancer trials Research (Navitoclax) Quercetin alone Uncertain Low Oral Limited OTC

FOXO4-DRI offers the highest reported selectivity for senescent cells (11.73-fold in vitro). Dasatinib plus quercetin has more human data but comes with significant side effects from dasatinib, which is a cancer drug. Fisetin is the most accessible but likely the least potent. The choice depends on risk tolerance, access, and how aggressive the approach to senescent cell clearance needs to be.

Success Tips

Understand the Goal

FOXO4-DRI is not a daily supplement. It is a targeted intervention designed to clear accumulated cellular debris. Think of it like a deep cleaning rather than routine maintenance. The treatment happens, the clearing happens, and then the body is allowed to regenerate before considering another round.

Start Conservative

With an uncharacterized compound affecting a critical pathway, starting at the lower end of suggested doses makes sense. Dosing can always be increased on subsequent cycles if the initial treatment is well tolerated and more aggressive clearance is desired.

Track Your Biomarkers

For those serious about assessing the effects of senolytic treatment, baseline bloodwork before the cycle is recommended. Consider markers such as inflammatory cytokines (IL-6, TNF-alpha, CRP), kidney function (creatinine, BUN), and liver function. Repeat testing 4 to 6 weeks after treatment to assess changes.

Time It Thoughtfully

Some practitioners suggest timing senolytic treatments away from periods of high physical stress. The clearance phase may temporarily increase demands on the system as dying cells are processed.

Consider Synergistic Compounds

Some protocols combine FOXO4-DRI with other longevity compounds, though data on combinations is scarce. Theoretically, fisetin or quercetin (which have their own senolytic activity) might complement FOXO4-DRI, but stacking senolytics raises questions about excessive cell clearance. Most conservative approaches use one senolytic strategy at a time.

Foundation First

No peptide protocol compensates for poor sleep, nutrition, and exercise habits. The people who benefit most from longevity interventions are typically those who already have the basics optimized.

Storage and Handling

Before Reconstitution

• Store lyophilized (powder) vials in the freezer at −20°C
• Can also be stored in the refrigerator at 2°C to 8°C for shorter periods
• Protect from light
• Do not use past the expiration date

After Reconstitution

• Refrigerate at 2°C to 8°C
• Use within 7 days for optimal potency
• Do not freeze after reconstitution
• Keep the stopper clean between uses
• If the solution becomes cloudy or contains particles, discard and use a new vial

FOXO4-DRI is a larger peptide (46 amino acids) and may be more sensitive to degradation than smaller compounds. Handle with care and do not leave at room temperature for extended periods.

Legal Status

United States: Not FDA approved. Available through research chemical suppliers as a research compound. International: Not approved for clinical use in most countries. Available for research purposes. Research Status: Strong preclinical data. No completed human clinical trials. The original discovery team continues research on next-generation compounds.

Product Source

FOXO4-DRI (Proxofim) is available through research peptide suppliers. Only use suppliers that have 99% or greater purity, verified by HPLC and mass spectrometry and synthesized and lyophilized in the USA. FOXO4-DRI is sold for research purposes only and is not intended for human consumption.

Frequently Asked Questions

How is FOXO4-DRI different from quercetin or fisetin? Quercetin and fisetin are natural compounds with mild senolytic activity through multiple mechanisms. FOXO4-DRI is a synthetic peptide that specifically targets the FOXO4-p53 interaction that keeps senescent cells alive. The specificity of FOXO4-DRI (11.73-fold selectivity) is much higher than natural senolytics, meaning it more precisely targets senescent cells while sparing healthy cells. Why do protocols use such short cycles? Senescent cell clearance is an acute intervention, not chronic therapy. The goal is to eliminate accumulated dysfunctional cells, then allow healthy tissue to regenerate. Continuous treatment would not provide additional benefit and could increase the risk of off-target effects. Short cycles repeated annually address new senescent cells that accumulate over time. Will I feel the effects immediately?

Some users report gradual improvements in energy, pain levels, and function over the weeks following treatment. Others notice little subjective change despite potential cellular benefits. The clearance process itself may cause temporary fatigue as the body processes dying cells. Dramatic overnight changes are unlikely. Is it safe given that it affects p53? p53 is indeed a critical tumor suppressor. The key is that FOXO4-DRI specifically disrupts the FOXO4-p53 interaction that exists primarily in senescent cells. Healthy cells do not rely on this particular interaction for survival, so they are largely unaffected. However, the lack of human clinical data means long-term safety is unknown, which is why conservative dosing and limited treatment frequency are recommended. How do I know if I have senescent cells to clear? Everyone over 40 has accumulated some senescent cells. The burden increases with age, chronic stress, poor metabolic health, and prior chemotherapy or radiation exposure. There is no readily available clinical test for senescent cell burden. Most people treating with senolytics are doing so based on age and the assumption that clearance will provide benefit. Can I combine this with other longevity compounds? Some practitioners combine FOXO4-DRI with NAD+ precursors, metformin, or other longevity compounds. Data on combinations is essentially nonexistent. The theoretical concern with combining multiple senolytics (such as FOXO4-DRI with dasatinib plus quercetin) is excessive cell clearance. Most conservative approaches use one senolytic strategy at a time. What is FOXO4-DRI not? FOXO4-DRI is not a cosmetic anti-aging peptide, a daily longevity supplement, a stimulant or metabolic enhancer, or a compound proven safe or effective in large-scale human trials. It is a powerful experimental senolytic and should be approached conservatively and scientifically.

References

1. Baar MP, Brandt RMC, Putavet DA, et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell. 2017;169(1):132-147. 2. Zhang C, Xie Y, Chen H, et al. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging (Albany NY). 2020;12(2):1272-1284. 3. Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nature Medicine. 2018;24:1246-1256. 4. Le HQ, Lie KK, Giroud-Gerbetant J, et al. (Huang Y, He Y, Makarcyzk MJ, Lin H.) Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes. Frontiers in Bioengineering and Biotechnology. 2021;9:677576.

5. Bourgeois B, Gui T, Lazaro D, et al. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nature Communications. 2025;16:4914. 6. Demaria M, Ohtani N, Youssef SA, et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Developmental Cell. 2014;31(6):722- 733. 7. Kirkland JL, Tchkonia T. Cellular senescence: a translational perspective. EBioMedicine. 2017;21:21-28. 8. de Keizer PLJ. The Fountain of Youth by Targeting Senescent Cells? Trends in Molecular Medicine. 2017;23(9):751-762.